Stock futures dipped on Thursday as investors weighed President Trump’s 90-day tariff reprieve for select countries, which ...

Dexcom (Nadsaq:DXCM) announced today that the FDA cleared its G7 15-day continuous glucose monitoring (CGM) system.

DexCom DXCM underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Dexcom (DXCM – Research Report), with a price ...

Mizuho analyst Anthony Petrone initiated coverage of DexCom (DXCM) with an Outperform rating and $85 price target The firm cites its positive ...

DexCom (NasdaqGS:DXCM) experienced an 12% decline over the past week, during which the company transitioned its audit from Ernst & Young to Deloitte & Touche, and appointed Jon Coleman as Chief ...

In its fourth quarter 2024 investor letter, Sands Capital Select Growth Fund emphasized stocks such as DexCom, Inc.

Explore DexCom stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for DXCM. Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom DexCom ...

DexCom Inc. closed 52.68% below its 52-week high of $141.25, which the company reached on April 11th.

Shares of DexCom Inc. DXCM slipped 1.53% to $60.69 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 1.57% to 4,982.77 and Dow ...

Markets are assessing the latest fallout from President Trump's fast-moving tariff plans, which led to a whipsawing session on Monday. Shares of Broadcom (AVGO) rose in after-hours trading after ...

The San Diego-based medical device company stated that the Dexcom G7 15 Day has an overall Mean Absolute Relative Difference (MARD) of 8.0%, showcasing its precision in glucose level readings. The ...